Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Platelet-rich plasma (PRP) autologous eye drops are a topical ophthalmic biologic therapy used for the treatment of severe dry eye disease and corneal damage. Developed as a clinical service by Enrich PRP (Enrich Advanced Eye Care), the drops are prepared from a patient's own blood, resulting in a 100% biological, preservative-free formulation. The preparation contains a high concentration of platelets that release essential growth factors—including Platelet-Derived Growth Factor (PDGF), Transforming Growth Factor beta (TGF-β), and Epidermal Growth Factor (EGF)—and cytokines to promote tissue repair, corneal epithelial healing, and nerve regeneration. Unlike standard autologous serum eye drops, PRP eye drops provide a more concentrated healing modality specifically suited for severe ocular surface disease where traditional therapies have failed.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on platelet-rich plasma autologous eye drops.